C
Charles A. Butts
Researcher at University of Alberta
Publications - 9
Citations - 620
Charles A. Butts is an academic researcher from University of Alberta. The author has contributed to research in topics: Lung cancer & Lean body mass. The author has an hindex of 5, co-authored 9 publications receiving 525 citations. Previous affiliations of Charles A. Butts include Cross Cancer Institute.
Papers
More filters
Journal ArticleDOI
Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.
Carla M. Prado,Vickie E. Baracos,Linda J. McCargar,Marina Mourtzakis,Karen E. Mulder,Tony Reiman,Charles A. Butts,Andrew Scarfe,Michael B. Sawyer +8 more
TL;DR: Low LBM is a significant predictor of toxicity in female patients administered 5-FU using the convention of dosing per unit of body surface area, and it is concluded that variation in toxicity between females and males may be partially explained by this feature of body composition.
Journal ArticleDOI
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
Michael P. Chu,Sunita Ghosh,Carole R Chambers,Naveen S. Basappa,Charles A. Butts,Quincy Chu,David William Fenton,Anil A. Joy,Randeep Sangha,Michael Smylie,Michael B. Sawyer +10 more
TL;DR: This large population-based study suggests erlotinib efficacy might be linked with gastric pH and OS could be adversely affected, and is the first study demonstrating a possible negative clinical effect of coadministration of erlot inib with AS therapy.
Journal ArticleDOI
Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: a case report and review of the literature.
Tony Reiman,Charles A. Butts +1 more
TL;DR: Gastrointestinal bleeding from metastatic breast cancer is an uncommon presentation that is readily diagnosed and that can be treated successfully by endoscopic hemostatic therapy.
Journal ArticleDOI
Is lobectomy superior to sublobar resection for early-stage small-cell lung cancer discovered intraoperatively?
TL;DR: Although both lobectomy and SLR are associated with improved survival compared with non-surgical treatment in early-stage SCLC, lobectomy is superior, although there is potential for selection bias and stage migration.
Journal ArticleDOI
Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
Anil A. Joy,Charles A. Butts +1 more
TL;DR: A number of MoAbs targeting EGFR are currently in development and their clinical usefulness in the treatment of NSCLC is discussed, with particular attention given to cetuximab.